Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15023269 | 0.86 | ALDH1A1 (0.61) | ALDH1A1MAPTPKMHPGDSMN1; SMN2 | |
| SCHEMBL15033607 | 0.81 | LMNA (0.68) | ALDH1A1MAPTPKMHPGDSMN1; SMN2 | |
| SCHEMBL15033592 | 0.78 | HPGD (0.53) | ALDH1A1MAPTPKMHPGDSMN1; SMN2 | |
| SCHEMBL15033598 | 0.78 | ALDH1A1 (0.61) | ALDH1A1MAPTPKMHPGDSMN1; SMN2 | |
| SCHEMBL15033604 | 0.77 | NPC1 (1.00) | ALDH1A1MAPTHPGDSMN1; SMN2NPC1 | |
| SCHEMBL9492258 | 0.75 | HPGD (0.78) | HPGDSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL9492505 | 0.75 | HPGD (0.78) | HPGDSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL27750343 | 0.75 | NPC1 (0.68) | ALDH1A1MAPTHPGDSMN1; SMN2NPC1 | |
| SCHEMBL27451737 | 0.75 | NPC1 (0.68) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL10792384 | 0.73 | HPGD (0.81) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION | CASE WESTERN RESERVE UNIVERSITY | 2013-06-20 | — | — | US | disclosed |
| US-20130158112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION | CASE WESTERN RESERVE UNIVERSITY | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION | IAPP, APP, BACE1 | ALDH1A1 4152/4885MAPT 38/4885PKM 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.